STTK
What one share of Shattuck Labs holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases.
Shattuck Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.50 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.39 |
| Cash and investments | $0.63 |
| Book value | $2.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $1.31 | −$3.17 | $0.06 | −$2.84 | — | −$4.55 |
| 2020 | $0.64 | −$2.36 | $0.05 | −$2.22 | — | — |
| 2021 | $0.71 | −$1.07 | $0.19 | −$1.55 | — | $6.42 |
| 2022 | $0.02 | −$2.41 | $0.27 | −$2.50 | — | $4.16 |
| 2023 | $0.04 | −$2.05 | $0.01 | −$1.92 | — | $3.06 |
| 2024 | $0.11 | −$1.49 | $0.00 | −$1.19 | — | $1.67 |
| 2025 | $0.01 | −$0.70 | $0.00 | −$0.57 | — | $1.30 |